Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNEGAS KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNEGAS KIT.
DRAXIMAGE MDP-25 vs TECHNEGAS KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Technetium Tc-99m generator that produces pertechnetate ion, which is taken up by thyroid, salivary glands, stomach, and choroid plexus; also used for radiolabeling of other compounds.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
Inhalation: 740-1110 MBq (20-30 mCi) of Technetium-99m DTPA aerosol, administered via nebulizer over 3-5 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Physical half-life of 99mTc: 6.02 hours; effective half-life after inhalation: approximately 6.02 hours (clearance limited by physical decay, as the agent is inert)
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Renal: 100% as unchanged pertechnetate (99mTcO4-); biliary/fecal: negligible
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical